A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901

Amrubicin, a third-generation synthetic anthracycline agent, has favorable clinical activity and acceptable toxicity for the treatment of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer. We conducted this study to evaluate the efficacy and safety of amrubicin for advanced...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Harada, Toshiyuki, Oizumi, Satoshi, Ito, Kenichiro, Takamura, Kei, Kikuchi, Eiki, Kuda, Tomoya, Sugawara, Shunichi, Suzuki, Aya, Maemondo, Makoto, Fujita, Yuka, Kinoshita, Ichiro, Inoue, Akira, Hommura, Fumihiro, Katsuura, Yutaka, Dosaka-Akita, Hirotoshi, Isobe, Hiroshi, Nishimura, Masaharu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2013
Gaiak:
Lung Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639531/
https://ncbi.nlm.nih.gov/pubmed/23442308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0308
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak